Estimaciones de analistas de Wall Street para Cardiff Oncology, Inc. (CRDF): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.14 | ||
| 2026-08-11 | $-0.14 | $-0.12 | -17.0% |
| 2026-05-14 | $-0.18 | $-0.13 | -38.5% |
| 2026-02-24 | $-0.11 | $-0.18 | +38.9% |
| 2025-11-06 | $-0.17 | $-0.20 | +15.0% |
| 2025-07-29 | $-0.21 | $-0.19 | -10.5% |
| 2025-05-08 | $-0.20 | $-0.19 | -5.3% |
| 2025-02-27 | $-0.21 | $-0.26 | +19.2% |
Ratios de valoración
| Precio / Valor contable | 3.63 |
| EV / EBITDA | -1.93 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $381000 | $505000 | $378000 | $244632 | $366000 | $359000 | $386000 | $488000 | $683000 | $593000 |
| Coste de Ventas | $1.7M | $1.8M | $597000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$1.3M | -$1.3M | -$219000 | $244632 | $366000 | $359000 | $386000 | $488000 | $683000 | $593000 |
| I+D | $15.0M | $7.9M | $8.2M | $11.2M | $11.2M | $17.4M | $27.1M | $32.9M | $36.9M | $35.3M |
| Generales y Administrativos | $23.0M | $14.2M | $8.0M | $5.8M | $8.2M | $11.8M | $13.2M | $13.0M | $12.5M | $14.2M |
| Gastos Operativos | $38.0M | $22.1M | $16.2M | $16.9M | $19.5M | $29.2M | $40.3M | $45.9M | $49.3M | $49.6M |
| Beneficio Operativo | -$40.1M | -$25.6M | -$17.1M | -$16.7M | -$19.1M | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| EBITDA | -$36.8M | -$22.8M | -$15.7M | -$15.9M | -$18.8M | -$27.8M | -$38.5M | -$41.0M | -$45.0M | -$44.9M |
| Gastos por Intereses | $1.4M | $1.0M | $25409 | 0 | $2000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Impuestos | -$296000 | $716000 | $617643 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| BPA | $-93.54 | $-51.71 | $-7.06 | $-2.70 | $-1.08 | $-0.73 | $-0.89 | $-0.93 | $-0.95 | $-0.69 |
| BPA Diluido | $-93.22 | $-51.71 | $-7.06 | $-2.70 | $-1.08 | $-0.73 | $-0.89 | $-0.93 | $-0.95 | $-0.69 |
| Acciones en Circulación (Diluidas) | $420568 | $481665 | $2.3M | $6.0M | $20.9M | $39.0M | $43.6M | $44.7M | $47.6M | $66.8M |
Precio
| Precio | $1.35 |
| Capitalización | $104M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explorar sector: Healthcare · Biotechnology
Más secciones de CRDF: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones